Jiangsu Hengrui Pharmaceuticals Co., Ltd.
CIK: 0002080343
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)3 (100.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SEC CIK 0002080343) files insider reports with the SEC as 10% Owner of Braveheart Bio, Inc. (BRVE) and 10% Owner of Kailera Therapeutics, Inc. (KLRA).
Signal8 holds 4 ownership filings by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (2 Form 3, 2 Form 4), filed between Apr 16, 2026 and Aug 10, 2026. Those filings report 3 transactions, from Apr 20, 2026 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s filings is in LIANYUNGANG.
Recent filings by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Other insiders filing for Braveheart Bio, Inc. (BRVE)
- Agarwala Vineeta, Director
- AH Bio Fund IV, L.P., 10% Owner
- Chimovits Erez, Director
- ORBIMED ADVISORS LLC, Director
- Forbion Growth Opportunities Fund III Cooperatief U.A., 10% Owner
- Rickey James Paul, Chief Financial Officer